Cryptococcal meningitis: improving access to essential antifungal medicines in resource-poor countries
- 1 July 2013
- journal article
- research article
- Published by Elsevier BV in The Lancet Infectious Diseases
- Vol. 13 (7), 629-637
- https://doi.org/10.1016/s1473-3099(13)70078-1
Abstract
No abstract availableKeywords
This publication has 55 references indexed in Scilit:
- Driving a decade of change: HIV/AIDS, patents and access to medicines for allJournal of the International AIDS Society, 2011
- A win-win solution?: A critical analysis of tiered pricing to improve access to medicines in developing countriesGlobalization and Health, 2011
- A Novel Tropically Stable Oral Amphotericin B Formulation (iCo-010) Exhibits Efficacy against Visceral Leishmaniasis in a Murine ModelPLoS Neglected Tropical Diseases, 2010
- Improving Outcome of Treatment of Kala-Azar by Supplementation of Amphotericin B with Physiologic Saline and Potassium ChlorideThe American Journal of Tropical Medicine and Hygiene, 2010
- Combination Flucytosine and High‐Dose Fluconazole Compared with Fluconazole Monotherapy for the Treatment of Cryptococcal Meningitis: A Randomized Trial in MalawiClinical Infectious Diseases, 2010
- Clinical Practice Guidelines for the Management of Cryptococcal Disease: 2010 Update by the Infectious Diseases Society of AmericaClinical Infectious Diseases, 2010
- Screening for Cryptococcal Antigenemia in Patients Accessing an Antiretroviral Treatment Program in South AfricaClinical Infectious Diseases, 2009
- Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDSAIDS, 2009
- Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysisThe Lancet, 2009
- Oral versus Intravenous Flucytosine in Patients with Human Immunodeficiency Virus-Associated Cryptococcal MeningitisAntimicrobial Agents and Chemotherapy, 2007